AZD9833 + Fulvestrant
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced ER-Positive HER2-Negative Breast Cancer
Conditions
Advanced ER-Positive HER2-Negative Breast Cancer
Trial Timeline
Apr 22, 2020 → Mar 17, 2026
NCT ID
NCT04214288About AZD9833 + Fulvestrant
AZD9833 + Fulvestrant is a phase 2 stage product being developed by AstraZeneca for Advanced ER-Positive HER2-Negative Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04214288. Target conditions include Advanced ER-Positive HER2-Negative Breast Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced ER-Positive HER2-Negative Breast Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04214288 | Phase 2 | Active |
Competing Products
20 competing products in Advanced ER-Positive HER2-Negative Breast Cancer